Hansa Biopharma AB (publ) (HNSA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the Hansa Biopharma second quarter and first half year 2026 financial results conference call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Hansa Biopharma CEO, Renée Aguirre-Lucander. Please go ahead. Thank you very much. Good afternoon and good morning, everybody. Welcome to the Hansa Biopharma Conference call to review the Q2 results for 2026. I'm Renée Aguirre-Lucander, CEO for Hansa Biopharma. Joining me today is Adam Cutler, Chief Financial Officer, Richard Philipson, Chief Medical Officer, and Maria Tarnson, Chief Operating Officer and President of the US. Please turn to the next page. Please allow me to draw your attention to the fact that we'll be making forward-looking statements during the presentation, and you should therefore apply appropriate caution. Next slide, please. This is the brief agenda for today's call. Next slide, please. So, looking at this quarter, I believe that it was a transformative quarter for HAMSA. By partnering in Europe, we strengthened the commercial support for Idoferix, both in terms of resources and experience, which will enhance patient access and ensure long-term success. In the short term, this can have a somewhat negative impact on financial performance due to the inherent uncertainties, which always comes with change. But strategically and long-term, I strongly believe that this was the right decision for t...